HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Nanjing Perlove Medical Equipment / Equity Capital Markets

<ul>
<li>Perlove’s strategy is high cost effectiveness to compete for market share. Although Perlove has achieved localization of some core components, detectors and algorithms of high-end equipment still rely on imports</li>
<li>Due to the lack of high-end product line layout, the positioning of mid-to-low end products makes it difficult for Perlove to obtain brand premium, thereby affecting profit margin performance. </li>
<li>Under the logic of import substitution, United Imaging and Wandong will benefit more than Perlove. Valuation of Perlove should be lower than United Imaging and Wandong. </li>
</ul>


Perlove’s strategy is high cost effectiveness to compete for market share. Although Perlove has achieved localization of some core components, detectors and algorithms of high-end equipment still rely on imports
Due to the lack of high-end product line layout, the positioning of mid-to-low end products makes it difficult for Perlove to obtain brand premium, thereby affecting profit margin performance. 
Under the logic of import substitution, United Imaging and Wandong will benefit more than Perlove. Valuation of Perlove should be lower than United Imaging and Wandong. 


Pre-IPO Nanjing Perlove Medical Equipment - Valuation Should Be Lower than Peers

China

Nanjing Perlove Medical Equipment (PME HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Nanjing Perlove Medical Equipment - Valuation Should Be Lower than Peers

​Perlove focuses on cost effectiveness but struggles with high-end product R&D, impacting brand premium/profit margins compared to peers, who will...

Xinyao (Criss) Wang

Perlove focuses on cost effectiveness but struggles with high-end product R&D, impacting brand premium/profit margins compared to peers, who will...